Validation of 13 pre-indications 18/12/2019

The 13 first-line pre-indications validated by the Operating Committee correspond to clinical indications positively evaluated by the british National Health Service (NHS).

Read more
Launch of a new campaign to prioritize pre-indications 12/11/2019

Dissemination of a questionnaire to the rare diseases and cancer care professionals for the submission of pre-indication projects. It explains: the interest of sequencing the complete genome in the patient care pathway, the technical constraints, the organisation to be set up and the expected volumes.

Read more
1st meeting around DEFIDIAG pilot project 04/11/2019

DEFIDIAG is a clinical trial in intellectual deficiency.

Read more
Implementation of the first two platforms SeqOIA and AURAGEN 30/09/2017

Choice of sequence technologies, definition of storage and calculation architecture which will be deployed (shared memory calculator, computing cluster…), software specification (purchase of licences, software compliance) .

Read more
Information notices and patient consent forms made available for genetic testing in a health care setting (rare diseases and cancers). 12/06/2019

In June 2019, information notices and consent forms – in their various forms: rare diseases, cancer; adults, minors, protected persons– were made available to the genomic platforms of the plan to be used during interviews with the first patients. These documents were created as “draft” versions: Obtaining consent in genetics is organised primarily by regulation […]

Read more
Launch of the 1st pre-indication prioritisation campaign 12/12/2018

Dissemination of a questionnaire to the rare disease and cancer care sectors for the submission of pre-indication projects. The interest of complete genome sequencing in the patient care pathway, the technical constraints, the organisation to be set up and the expected volumes are presented.

Read more
Mapping of the entire training offer of French universities and public sector engineer schools 12/02/2018

Poll of the entire training offer of French universities and public sector engineering schools through their web sites, including the training offer of medicine research and training units (UFR). This first objective was to identify the training that we believe to be necessary to deploy the French Plan for Genomic Medicine 2025. Only immediate vocational […]

Read more
Start of work on information notices and patient consent forms – principle of free and informed consent – for genetic testing in a health care setting (rare diseases and cancers) 27/01/2017

The first task addressed by the working group was to provide professionals with operational documents in an ethical manner, necessary to start the first sequencing.     Indeed, two types of documents must be submitted to patients by the medical specialist before any diagnosis in the framework of the plan: The information notice provides, in written and […]

Read more
Creation of working group in charge of two measures 27/09/2016

The “Ethics, regulation and society” working group is led by:  the Directorate-General for Health  under the aegis of Arnaud de Guerra (DGS), Aviesan, with Anne Cambon-Thomsen, director of research director, CNRS, member of the European Group on Ethics in Science and New Technologies, and Christine Lemaitre, representative of the Ethics Committee, Inserm. This group includes the various […]

Read more
Via Inserm, Aviesan, is a member of the International Consortium for personalised medicine, ICPerMed 12/09/2016

ICPerMed was launched at workshops organised by the European Commission. It includes non-profit public and private bodies for funding health research and the setting up of public policies. ICPerMed wants to contribute to the implementation of personalised medicine for the benefit of patients, citizens and society as a whole and to facilitate the coordination of research […]

Read more